CVS Health is committed to lowering health care costs while delivering high-quality care to communities across the country. Learn more: https://cvshealth.com/thought-leadership/addressing-rising-health-care-costs
10 Essential Facts About Medicare and Prescription Drug SpendingKFF
Total US prescription drug spending is projected to grow from $298 billion in 2014 to $597 billion in 2025. Medicare spending on prescription drugs grew from $205 billion in 2005 to $341 billion in 2016 and is projected to reach $597 billion in 2025. The top 10 drugs by Medicare spending in 2015 accounted for 79% of total Medicare Part D spending, with Harvoni alone accounting for 5.1% of spending. Average annual growth in Medicare Part D spending per enrollee is projected to be 15% from 2016 to 2026.
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...CVS Health
Remarks by Thomas M. Moriarty, Executive Vice President, Chief Strategy Officer and General Counsel at the National Association of Attorneys Generals’ April 2017 Summit.
For more on the event, please visit: https://cvshealth.com/thought-leadership/making-progress-how-public-and-private-stakeholders-are-collaborating-to-improve-care
This document discusses Medicaid managed care and the implications of the Medicaid Managed Care Final Rule. It provides an overview of the growth of Medicaid and managed care within Medicaid. It outlines Aetna's footprint in Medicaid managed care. The main provisions of the Final Rule that impact managed care are summarized, including requirements around actuarial soundness, phasing out of pass-through payments, strengthening network adequacy standards, aligning provider screening and enrollment processes, and standardizing information requirements for enrollees. The document concludes that the Final Rule modernizes Medicaid managed care practices and oversight to be more consistent with Medicare Advantage and Marketplace plans.
Prescription Medicines Costs in Context April 2022PhRMA
This document discusses the costs of prescription medicines in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID treatments. While brand medicine prices declined slightly in 2020, overall medicine spending grew modestly due to rebates and discounts. The majority of medicine spending goes to entities other than the manufacturers, such as insurers, pharmacy benefit managers, and providers. The document argues for reforms that make insurance work better for patients, modernize Medicare drug coverage, protect safety net programs, and end misaligned incentives in the system.
Wisconsin’s BadgerCare Plus Coverage Expansion: Early Evaluation Resultssoder145
Wisconsin expanded its BadgerCare Plus (BC+) program in 2008 with three main components: eligibility expansion, administrative simplification, and outreach efforts. An evaluation found large enrollment increases among children and parents, exceeding projections. The majority of new enrollees were already eligible. Auto-enrollment of eligible children was effective. Exits increased initially but are leveling off. While the expansion was successful, officials are concerned about rising costs. The evaluation suggests eligibility expansions coupled with simplification and outreach can increase participation, and auto-enrollment is promising for enrolling newly eligible populations.
Using the National Health Interview Survey to Evaluate State Health Reform: ...soder145
This study used data from the National Health Interview Survey to evaluate the impacts of health reform efforts in New York and Massachusetts on health insurance coverage, access to care, and health care use. The researchers found:
1) New York's incremental reform modestly increased coverage for lower-income adults but did not significantly improve access to or use of care.
2) Massachusetts' comprehensive reform substantially increased coverage overall and for lower-income adults, and led to some gains in access to and use of care in the early reform period likely due to increased coverage.
3) However, the analyses were limited by small sample sizes, particularly for Massachusetts, and a short time period after Massachusetts' reform to fully assess the impacts
10 Essential Facts About Medicare and Prescription Drug SpendingKFF
Total US prescription drug spending is projected to grow from $298 billion in 2014 to $597 billion in 2025. Medicare spending on prescription drugs grew from $205 billion in 2005 to $341 billion in 2016 and is projected to reach $597 billion in 2025. The top 10 drugs by Medicare spending in 2015 accounted for 79% of total Medicare Part D spending, with Harvoni alone accounting for 5.1% of spending. Average annual growth in Medicare Part D spending per enrollee is projected to be 15% from 2016 to 2026.
National Association of Attorneys Generals’ Presidential Initiative Summit Ap...CVS Health
Remarks by Thomas M. Moriarty, Executive Vice President, Chief Strategy Officer and General Counsel at the National Association of Attorneys Generals’ April 2017 Summit.
For more on the event, please visit: https://cvshealth.com/thought-leadership/making-progress-how-public-and-private-stakeholders-are-collaborating-to-improve-care
This document discusses Medicaid managed care and the implications of the Medicaid Managed Care Final Rule. It provides an overview of the growth of Medicaid and managed care within Medicaid. It outlines Aetna's footprint in Medicaid managed care. The main provisions of the Final Rule that impact managed care are summarized, including requirements around actuarial soundness, phasing out of pass-through payments, strengthening network adequacy standards, aligning provider screening and enrollment processes, and standardizing information requirements for enrollees. The document concludes that the Final Rule modernizes Medicaid managed care practices and oversight to be more consistent with Medicare Advantage and Marketplace plans.
Prescription Medicines Costs in Context April 2022PhRMA
This document discusses the costs of prescription medicines in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID treatments. While brand medicine prices declined slightly in 2020, overall medicine spending grew modestly due to rebates and discounts. The majority of medicine spending goes to entities other than the manufacturers, such as insurers, pharmacy benefit managers, and providers. The document argues for reforms that make insurance work better for patients, modernize Medicare drug coverage, protect safety net programs, and end misaligned incentives in the system.
Wisconsin’s BadgerCare Plus Coverage Expansion: Early Evaluation Resultssoder145
Wisconsin expanded its BadgerCare Plus (BC+) program in 2008 with three main components: eligibility expansion, administrative simplification, and outreach efforts. An evaluation found large enrollment increases among children and parents, exceeding projections. The majority of new enrollees were already eligible. Auto-enrollment of eligible children was effective. Exits increased initially but are leveling off. While the expansion was successful, officials are concerned about rising costs. The evaluation suggests eligibility expansions coupled with simplification and outreach can increase participation, and auto-enrollment is promising for enrolling newly eligible populations.
Using the National Health Interview Survey to Evaluate State Health Reform: ...soder145
This study used data from the National Health Interview Survey to evaluate the impacts of health reform efforts in New York and Massachusetts on health insurance coverage, access to care, and health care use. The researchers found:
1) New York's incremental reform modestly increased coverage for lower-income adults but did not significantly improve access to or use of care.
2) Massachusetts' comprehensive reform substantially increased coverage overall and for lower-income adults, and led to some gains in access to and use of care in the early reform period likely due to increased coverage.
3) However, the analyses were limited by small sample sizes, particularly for Massachusetts, and a short time period after Massachusetts' reform to fully assess the impacts
Making use of All-Payer Claims Databases for Health Care Reform Evaluationsoder145
This document discusses the uses of all-payer claims databases (APCDs) for health care reform evaluation. APCDs contain claims data from multiple payers and can be used to monitor health care costs, identify cost drivers, foster price transparency, and track quality measures. The document outlines several state case studies that demonstrate how APCDs have been used to monitor statewide spending, evaluate transformation efforts, and promote price transparency. It concludes by discussing future directions for APCDs, including data linkages and payment reform evaluation.
Coverage and Access to Care for Children with Chronic Health Conditions in th...soder145
The document discusses how the Affordable Care Act (ACA) improved insurance coverage and access to care for children with pre-existing conditions. It finds that after the ACA, adolescents (12-17 years) with chronic health conditions were less likely to be uninsured or delay/forgo care due to cost. However, similar improvements were not seen for younger children. This represents an early estimate as the 2010 ACA mandate lacked community rating provisions to limit premium costs for families of chronically ill children.
Fitting Square Pegs Into Round Holes: Linking Medicaid and Current Population...soder145
This document summarizes a study comparing Medicaid enrollment data from the Medicaid Statistical Information System (MSIS) to survey data from the Current Population Survey (CPS) to understand discrepancies between the two data sources. The study found the CPS significantly undercounted Medicaid enrollment compared to MSIS data. Measurement error in the CPS, particularly issues with question design and sample coverage, appear to contribute most to the undercount. Further analysis is still needed to fully understand and address the differences between the data sources.
Prescription Medicines Costs in Context March 2022PhRMA
This document discusses trends in prescription drug costs and spending in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID. While brand drug prices declined slightly in 2020, overall drug spending grew modestly. Most drug spending goes to health insurers, pharmacy benefit managers, and other entities rather than drug manufacturers. The majority of drugs dispensed are generics, which provide billions in savings each year. The document argues that while drug spending is projected to increase at a similar rate as overall healthcare costs, patients still face high out-of-pocket costs due to deductibles, coinsurance, and other cost-sharing policies by insurers.
This presentation discusses metrics and data sources for measuring the impact of state-level health reform. It identifies priority measures for health insurance coverage, affordability and comprehensiveness of coverage, and access to care. Existing data sources like surveys are identified, but there are also gaps, particularly for private insurance premiums and nongroup coverage comprehensiveness. Challenges in using population surveys across states are discussed. Planning is needed to uniformly collect high-priority data not currently available to accurately measure state health reform impacts.
Health Care Concerns: Rates and Trends During Health Reformsoder145
1) The document summarizes a panelist's presentation on consumer sentiment toward health reform. It discusses the creation of indices to track consumer confidence in health costs over time and reactions to health reform.
2) Three indices were created based on survey data - the Recent Health Cost Barrier Index, Future Health Cost Concern Index, and a composite RWJF Health Care Confidence Index. The future index appears more sensitive to health reform events.
3) While the reform debate has not shifted confidence levels overall, the importance of reform varies by demographics and is seen as very or somewhat important by a majority of respondents from April 2009 to May 2010.
Integration of health records in the prescription drug monitoring programAlayziaHarris
Through the Future of Florida Summit hosted by UF's Bob Graham Center, my team and I were tasked to find solutions to a current health issue. We wanted to focus on the opioid epidemic and tackle this crisis by implementing improvements towards regulation.
Vermont's 2006 health care reform law aimed to increase access to affordable health insurance. A key part was the Catamount Health public/private hybrid plan, which saw sharp enrollment growth initially. While take-up rates were higher among older groups, barriers to enrollment remain. Insurance coverage in Vermont increased significantly between 2005-2008, with growth in both public and private insurance. However, long-term sustainability faces challenges due to reliance on declining revenue sources and the economic downturn potentially impacting enrollment.
eRX Webinar - State Health Information Exchange Leadership ForumBrian Ahier
The document discusses various potential roles that states or state-designated entities (SDEs) can play in supporting electronic prescribing (ePrescribing) to help meet meaningful use requirements. It outlines conducting a gap analysis of ePrescribing capabilities; tracking adoption; developing education campaigns; examining regulations; coordinating stakeholder strategies; engaging pharmacies; updating Medicaid; increasing provider awareness; facilitating electronic prescribing of controlled substances; and monitoring emerging issues. Examples from Minnesota, Rhode Island, Florida and Tennessee are provided.
National Health Care Reform: The Proposals and the Politicssoder145
Presentation by Elizabeth Lukanen at the University of Minnesota Academic Health Center's Student Leadership Summit in Minneapolis, MN, December 5, 2009.
Mobile health applications are growing rapidly, with 72% of physicians currently using smartphones. The most popular platforms for medical apps are currently the iPhone and Blackberry. In the future, more apps will be developed for Android tablets and Windows Phone 7. Popular current medical apps include Epocrates for drug references, Medscape for extensive medical content and CME, and various clinical apps like Nimble that allow access to electronic health records from mobile devices. Remote monitoring apps are also emerging that allow monitoring patients from ICUs and during childbirth from mobile devices. Future directions include more "web apps" that can be accessed from any device and app stores within electronic health records to facilitate integration.
Prescription Medicines Costs in Context October 2020PhRMA
This document discusses the costs and affordability of prescription medicines in the United States. It notes that while spending on prescription medicines accounts for only 14% of total health care spending, patients face high and rising out-of-pocket costs for medicines. While most medicines sold in the US are generics, brand name medicines face significant price negotiations and rebates paid to insurers and pharmacy benefit managers that often do not lower costs for patients. The document outlines reforms to make medicines more affordable and accessible for patients.
Prescription Medicines Costs in Context January 2020PhRMA
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending represents 14% of total healthcare spending and a small portion of Medicaid spending, it has enabled breakthrough treatments for chronic diseases. While brand drug prices grew by 0.3% in 2018 after rebates, spending on other healthcare services is projected to grow 5 times faster than prescription drug spending through the next decade. The document also outlines how generics have reduced costs significantly, providing $1.99 trillion in savings over 10 years, and how biosimilars are expected to reduce brand drug sales by $95 billion from 2019-2023 through increased competition.
Prescription Medicines Costs in Context November 2019PhRMA
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare spending, patients often face high out-of-pocket costs. It outlines the significant costs and risks of drug research and development. The document also describes the role of generics in reducing costs over time and how rebates and discounts do not always lower costs for patients.
Making use of All-Payer Claims Databases for Health Care Reform Evaluationsoder145
This document discusses the uses of all-payer claims databases (APCDs) for health care reform evaluation. APCDs contain claims data from multiple payers and can be used to monitor health care costs, identify cost drivers, foster price transparency, and track quality measures. The document outlines several state case studies that demonstrate how APCDs have been used to monitor statewide spending, evaluate transformation efforts, and promote price transparency. It concludes by discussing future directions for APCDs, including data linkages and payment reform evaluation.
Coverage and Access to Care for Children with Chronic Health Conditions in th...soder145
The document discusses how the Affordable Care Act (ACA) improved insurance coverage and access to care for children with pre-existing conditions. It finds that after the ACA, adolescents (12-17 years) with chronic health conditions were less likely to be uninsured or delay/forgo care due to cost. However, similar improvements were not seen for younger children. This represents an early estimate as the 2010 ACA mandate lacked community rating provisions to limit premium costs for families of chronically ill children.
Fitting Square Pegs Into Round Holes: Linking Medicaid and Current Population...soder145
This document summarizes a study comparing Medicaid enrollment data from the Medicaid Statistical Information System (MSIS) to survey data from the Current Population Survey (CPS) to understand discrepancies between the two data sources. The study found the CPS significantly undercounted Medicaid enrollment compared to MSIS data. Measurement error in the CPS, particularly issues with question design and sample coverage, appear to contribute most to the undercount. Further analysis is still needed to fully understand and address the differences between the data sources.
Prescription Medicines Costs in Context March 2022PhRMA
This document discusses trends in prescription drug costs and spending in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID. While brand drug prices declined slightly in 2020, overall drug spending grew modestly. Most drug spending goes to health insurers, pharmacy benefit managers, and other entities rather than drug manufacturers. The majority of drugs dispensed are generics, which provide billions in savings each year. The document argues that while drug spending is projected to increase at a similar rate as overall healthcare costs, patients still face high out-of-pocket costs due to deductibles, coinsurance, and other cost-sharing policies by insurers.
This presentation discusses metrics and data sources for measuring the impact of state-level health reform. It identifies priority measures for health insurance coverage, affordability and comprehensiveness of coverage, and access to care. Existing data sources like surveys are identified, but there are also gaps, particularly for private insurance premiums and nongroup coverage comprehensiveness. Challenges in using population surveys across states are discussed. Planning is needed to uniformly collect high-priority data not currently available to accurately measure state health reform impacts.
Health Care Concerns: Rates and Trends During Health Reformsoder145
1) The document summarizes a panelist's presentation on consumer sentiment toward health reform. It discusses the creation of indices to track consumer confidence in health costs over time and reactions to health reform.
2) Three indices were created based on survey data - the Recent Health Cost Barrier Index, Future Health Cost Concern Index, and a composite RWJF Health Care Confidence Index. The future index appears more sensitive to health reform events.
3) While the reform debate has not shifted confidence levels overall, the importance of reform varies by demographics and is seen as very or somewhat important by a majority of respondents from April 2009 to May 2010.
Integration of health records in the prescription drug monitoring programAlayziaHarris
Through the Future of Florida Summit hosted by UF's Bob Graham Center, my team and I were tasked to find solutions to a current health issue. We wanted to focus on the opioid epidemic and tackle this crisis by implementing improvements towards regulation.
Vermont's 2006 health care reform law aimed to increase access to affordable health insurance. A key part was the Catamount Health public/private hybrid plan, which saw sharp enrollment growth initially. While take-up rates were higher among older groups, barriers to enrollment remain. Insurance coverage in Vermont increased significantly between 2005-2008, with growth in both public and private insurance. However, long-term sustainability faces challenges due to reliance on declining revenue sources and the economic downturn potentially impacting enrollment.
eRX Webinar - State Health Information Exchange Leadership ForumBrian Ahier
The document discusses various potential roles that states or state-designated entities (SDEs) can play in supporting electronic prescribing (ePrescribing) to help meet meaningful use requirements. It outlines conducting a gap analysis of ePrescribing capabilities; tracking adoption; developing education campaigns; examining regulations; coordinating stakeholder strategies; engaging pharmacies; updating Medicaid; increasing provider awareness; facilitating electronic prescribing of controlled substances; and monitoring emerging issues. Examples from Minnesota, Rhode Island, Florida and Tennessee are provided.
National Health Care Reform: The Proposals and the Politicssoder145
Presentation by Elizabeth Lukanen at the University of Minnesota Academic Health Center's Student Leadership Summit in Minneapolis, MN, December 5, 2009.
Mobile health applications are growing rapidly, with 72% of physicians currently using smartphones. The most popular platforms for medical apps are currently the iPhone and Blackberry. In the future, more apps will be developed for Android tablets and Windows Phone 7. Popular current medical apps include Epocrates for drug references, Medscape for extensive medical content and CME, and various clinical apps like Nimble that allow access to electronic health records from mobile devices. Remote monitoring apps are also emerging that allow monitoring patients from ICUs and during childbirth from mobile devices. Future directions include more "web apps" that can be accessed from any device and app stores within electronic health records to facilitate integration.
Prescription Medicines Costs in Context October 2020PhRMA
This document discusses the costs and affordability of prescription medicines in the United States. It notes that while spending on prescription medicines accounts for only 14% of total health care spending, patients face high and rising out-of-pocket costs for medicines. While most medicines sold in the US are generics, brand name medicines face significant price negotiations and rebates paid to insurers and pharmacy benefit managers that often do not lower costs for patients. The document outlines reforms to make medicines more affordable and accessible for patients.
Prescription Medicines Costs in Context January 2020PhRMA
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending represents 14% of total healthcare spending and a small portion of Medicaid spending, it has enabled breakthrough treatments for chronic diseases. While brand drug prices grew by 0.3% in 2018 after rebates, spending on other healthcare services is projected to grow 5 times faster than prescription drug spending through the next decade. The document also outlines how generics have reduced costs significantly, providing $1.99 trillion in savings over 10 years, and how biosimilars are expected to reduce brand drug sales by $95 billion from 2019-2023 through increased competition.
Prescription Medicines Costs in Context November 2019PhRMA
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare spending, patients often face high out-of-pocket costs. It outlines the significant costs and risks of drug research and development. The document also describes the role of generics in reducing costs over time and how rebates and discounts do not always lower costs for patients.
Prescription Medicines - Costs in Context January 2019PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Prescription Medicines - Costs In Context March 2019PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Prescription Medicines Costs in Context - June 2019PhRMA
We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches and enabling us to more effectively treat chronic disease, the biggest cost driver.
Prescription Medicines Costs in Context July 2021PhRMA
This document summarizes information from a report about prescription drug costs and spending in the United States. It notes that 53 new medicines were approved by the FDA in 2020 and discusses trends in drug spending growth rates remaining in line with overall health care spending increases. However, it also outlines challenges patients face in affording medications due to high deductibles, coinsurance, and other out-of-pocket costs not reduced by negotiated rebates and discounts. The report examines spending and policy issues across the entire U.S. health care system that contribute to the complex drug pricing landscape.
Prescription Medicines Costs in Context April 2021PhRMA
This document discusses the costs of prescription medicines in the United States. It notes that while brand medicine prices have risen 1.7% in 2019, in line with inflation, many patients still struggle with costs. It also discusses that prescription medicines make up only 14% of total healthcare spending in the US. Finally, it summarizes efforts by PhRMA to make medicines more affordable and accessible for patients.
The document discusses several issues impacting the global healthcare sector, including demographics, financial pressures, changes in the health industry, regulatory issues, medical advances, and emerging technologies. It notes that an aging population, rising rates of chronic diseases, and increasing consumerism are driving changes in healthcare. Healthcare costs continue to rise globally due to these factors, putting financial pressure on governments, insurers, and consumers. The healthcare industry is also transforming as physicians take on new roles, technology companies enter the space, and alternative payment models emerge. The document outlines some of the key regulatory issues around patient safety, cybersecurity, and fraud prevention. Finally, it briefly highlights several medical advances and how technologies like 3D printing, digital health apps,
Prescription Medicines - Costs in Context - September 2018PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Prescription Medicines - Costs in Context - September 2018PhRMA
Discussions about costs are important. We recognize that many are struggling to access the medicine they need, and have important questions about their medicine costs. And we want to help find the answers.
Prescription Medicines - Costs in Context - October 2018PhRMA
This document discusses the costs and context of prescription medicines. It notes that while prescription drug spending is a small percentage of total healthcare costs, certain patients face rising out-of-pocket costs. It also outlines the significant costs and risks of developing new medicines, with the average drug taking over 10 years and $2.6 billion to develop. The document proposes reforms to help lower costs for patients while supporting continued research and development of new treatments.
Prescription Medicines: Costs in Context June 2022PhRMA
This document discusses prescription drug costs and spending in the United States healthcare system. It notes that prescription drugs account for only 14% of total healthcare spending and that spending on drugs has remained stable as a share of overall costs. While new treatments have improved patient outcomes for conditions like cancer, overall drug costs are not expected to significantly impact total healthcare expenditures. The document also examines factors that influence patient affordability and access to medicines, such as the role of pharmacy benefit managers and hospitals.
Patient-centered medical home initiatives in several states have shown promising results in improving access to care, quality, and cost control for Medicaid patients. Oklahoma saw a $29 per patient annual reduction in Medicaid costs from 2008-2010 alongside increased use of preventive care. Colorado expanded Medicaid access from 20% to 96% of pediatricians at lower costs. Vermont saw 21-22% decreases in inpatient care use and costs from 2008-2010 alongside 31-36% drops in ER use and related costs. Washington state's acute care spending was 18% below average with 35% fewer inpatient stays per beneficiary. Overall, these initiatives demonstrate that the patient-centered medical home model can positively impact Medicaid programs.
Prescription Medicines: Costs in Context - June 2022PhRMA
The document summarizes information about prescription drug costs and spending in the United States. It notes that while new breakthrough medicines and treatments are being approved, prescription drug spending accounts for a small and stable share of total health care spending. Though net prices of brand name drugs have remained flat in recent years, other entities like PBMs, insurers, and hospitals receive an increasing portion of total drug spending. The document argues for reforms to make medicines more affordable and accessible for patients.
HCL's transformational Patient's first approach to HealthcareDebanjan Munsi
Digital Care management is the new buzzword in Healthcare technology, with the advent of digital technologies that track patient health, medicine subscriptions, dosages and create customized tracking, monitoring & delivery programs with regular dosage reminders, data driven insights on health vitals and patient routing to best possible treatment locations. Digital care management can not only reduce costs, but increase the vitality of healthcare programs, making them more efficient, decisive and customer friendly.
Chronic Care Improvement: How Medicare Transformation Can Save Lives, Save Mo...Steve Brown
Presentation by Steve Brown and Harris Miller introducing the ITAA Whitepaper: Chronic Care Improvement: How Medicare Transformation Can Save Lives, Save Money, and Stimulate an Emerging Technology Industry
Macro trends now and the future presentationCarla Hynes
Healthcare expenditures are expected to increase significantly in the coming years due to rising costs. Personal behaviors such as obesity and lack of preventative care contribute to growing health issues. The healthcare industry is shifting focus toward prevention and improved patient outcomes through increased use of technology, biotechnology, and telehealth. These macro trends are driving growth in management careers focused on areas like healthcare economics, technology, and biomedical engineering.
Healthcare expenditures are expected to increase significantly in the coming years due to rising costs. Personal behaviors such as obesity and lack of preventative care contribute to growing health issues. Trends in healthcare include increased use of technology, biotechnology, and focus on prevention and patient-centered care to improve outcomes. These macro trends are driving growth in management careers related to healthcare economics, technology, and biomedical fields.
Prescription Medicines: Costs in Context - May 2023PhRMA
This document discusses the costs of prescription medicines in the United States. It notes that while new medicines and treatments are improving patient outcomes, prescription drug costs make up a small and stable portion of total health care spending. However, the document also outlines ways that other entities like pharmacy benefit managers, hospitals, and insurers receive an increasing share of spending on brand medicines through rebates, fees, and price markups, shifting more costs onto patients. It calls for reforms to make medicines more affordable and ensure patients benefit from industry savings.
Similar to Addressing Rising Health Care Costs | CVS Health (20)
New CVS Health Poll Reveals That A Majority of U.S. Women Are Unaware of Thei...CVS Health
Results from a new national poll, commissioned by CVS Health (NYSE: CVS), reveal that while American women are increasingly aware of the dangers of heart disease and recognize it as the #1 killer of women, few acknowledge their personal risk factors that contribute to heart disease. Learn more: https://cvs.co/2s2OT0C
By the Numbers: Women’s Perceptions About Heart HealthCVS Health
American Heart Month, celebrated every February, is an important reminder to understand and address risks for heart disease – the number one killer of women in the United States. We conducted a survey of more than 1,100 women with Morning Consult in partnership with the American Heart Association, to learn about their perceptions of the importance of heart health and experiences managing heart-related conditions.
CVS Health Survey Reveals Majority of Americans Want Change to Improve the St...CVS Health
Results of a new national survey from CVS Health (NYSE: CVS) released today found that over half (56 percent) of Americans say the U.S. health care system does not work well for them, while overwhelming majorities agree the system is in need of reform (73 percent) and is currently too politicized (69 percent).
Learn more: https://cvs.co/StateofHealthcare
Politico Pro Health Care Briefing: Drug Safety and the Trump FDACVS Health
Opening remarks by Thomas M. Moriarty, Executive Vice President, Chief Strategy Officer and General Counsel at the Politico Pro Health Care Briefing: Drug Safety and the Trump FDA, April 5, 2017.
For more on CVS Health's work to ensure access to affordable drugs, visit: http://cvshealth.com/thought-leadership/drug-costs-efficiency-and-the-future-of-the-fda
Private Sector Solutions to America's Health Care ChallengesCVS Health
Keynote address by Thomas M. Moriarty, Executive Vice President, Chief Strategy Officer and General Counsel at the Bloomberg Intelligence Healthcare Summit, March 23, 2017.
CVS Health 2015 Corporate Social Responsibility ReportCVS Health
Making quality health care affordable, accessible and sustainable is the driving force behind our Prescription for a Better World Corporate Social Responsibility strategy.
It starts with our company purpose: CVS Health is committed to helping people on their path to better health. To ensure we focus our resources in the most appropriate and impactful manner, we continually assess which issues are most material to address.
Each year, we release the results of this assessment in our Corporate Social Responsibility Report.
Now in its ninth year, the report focuses on three pillars that support our strategy: Health in Action, Planet in Balance, and Leader in Growth.
• Through Health in Action, we bring quality health care that is affordable and accessible to our communities.
• Planet in Balance captures our focus on operating an environmentally sustainable business.
• Leader in Growth highlights the value we place on conducting business with integrity.
We invite you to explore this year’s report and share your feedback with us at CSR@CVSHealth.com.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
1. Lowest drug trend in 5 years
by leveraging lower-cost generics, strategic formulary management and
negotiated discounts and rebates for PBM members in 2017
Justsignupfor
ScriptSyncand
we’lldotherest.
Increasing medical costs impose a heavy
burden on patients and our health care system.
National health expenditures currently account
for 17.9% of our GDP and are expected to
increase to 19.9% by 20251
.
Tackling Rising
Drug Prices
Addressing Chronic
Disease Costs
Expanding Access
to Affordable Care
Improving Care
Coordination
Learn more at: cvshealth.com/thought-leadership/cost-of-care
1
Centers for Medicare and Medicaid Services data: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData
/NationalHealthAccountsHistorical.html
2
IQVIA Institute: https://www.iqvia.com/institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022
3
Partnership to Fight Chronic Disease Report: https://www.fightchronicdisease.org/latest-news/new-national-data-shows-projected-total-cost-chronic-disease-2016-2030-
america-42
4
Gallup Survey: http://news.gallup.com/poll/212780/cost-healthcare-americans-top-financial-tconcern.aspx
5
OECD Report: https://www.cnbc.com/2017/01/12/shocking-truth-20-of-health-care-expenditures-wasted-in-us-and-other-nations.html
Solutions to help make health care more
affordable for patients and taxpayers
Addressing Rising
Health Care Costs
1
2
3
4
CVS Health®
is
committed to lowering
health care costs
while delivering
high-quality care to
communities across
the country.
1. Rising Drug Prices
The average price of brand prescription drugs increased 58% from $231 to $364
over the past five years2
.
Savings passed directly to 10M members
negotiated rebates provided at point-of-sale to 10M PBM members
~90% spent < $300 OOP
nearly 90 percent of PBM members spent less than $300 out-of-pocket for
their prescription medicines in 2017
$420 average annual savings per patient
by identifying the lowest-cost medications through our Rx Savings Finder
We’re developing comprehensive programs to
lower drug costs for patients and payors:
2. Chronic Disease Costs
If rates of diseases such as obesity, diabetes and heart conditions continue to rise,
the cost to our health care system will reach $42 trillion between now and 20303
.
$0 copays
on medications for many chronic diseases through preventive
drug lists offered to payor clients
Increased adherence
as much as 1.8 percentage points in 2017 by designing plans
that connect chronic disease patients to lower-cost options
$3 saved for every $1 spent
on personalized interventions for patients through our
Pharmacy Advisor program
We’re implementing solutions to help manage costly
chronic diseases and improve outcomes for patients:
3. Access to Affordable Care
Americans rank the cost of health care as the most important financial problem
facing their family4
.
80% lower cost of care
through retail clinics (on average), compared to receiving
care through emergency rooms
Up to $3,000 savings
per at-home infusion treatment course through Coram,
compared to the same services provided in a health care facility
We’re expanding access to low-cost, high-quality
health care in communities and in the home:
4. Care Coordination
Waste and inefficiencies represent 20 cents of every dollar spent on health care5
.
50% fewer preventable readmissions
and an average of $1,300 savings per patient using pharmacist-led
medication reconciliation following a hospital stay
More than 70 collaborations
with major health systems to support joint clinical programs
and interoperable electronic health records
We’re providing savings by strengthening health
care integration and improving inefficiencies: